clofibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists 694 637-07-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clofibrate
  • ticlobran
  • xyduril
  • p-chlorophenoxyisobutyric acid ethyl ester
  • lipavil
  • lipavlon
  • lipomid
  • liprinal
  • miscleron
  • misclerone
A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)
  • Molecular weight: 242.70
  • Formula: C12H15ClO3
  • CLOGP: 3.68
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 35.53
  • ALOGS: -3.92
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 11 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.576 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.714 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 46.559 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 107.152 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 2.040 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 3.050 % Moderate 0.65
herg hERG pIC50 4.927 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 344.350 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 236.592 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 2.070 % Moderate 0.65
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK 41
kinase-selectivity-class ACVR2B,AXL,BRAF,ERBB2,GRK2,MAPK7,PDK4 7
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.353 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 395.367 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 3.830 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.593 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 3.600 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 332.660 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 49.540 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 4.080 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 8.147 uM Moderate 0.65

Approvals:

DateAgencyCompanyOrphan
Feb. 8, 1967 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35679 antilipemic drug
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:70782 PPARα agonist
CHEBI has role CHEBI:176497 geroprotector
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:24527 herbicide
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:83399 marine xenobiotic metabolite

Related Drugs by ATC class:

C10AB Fibrates 11 drugs
aluminium clofibratebezafibratecholine fenofibrateciprofibrateclofibrideetofibratefenofibrategemfibrozilpemafibrateronifibratesimfibrate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperlipidemia indication 55822004 DOID:1168
Partial Central Diabetes Insipidus off-label use




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST IC50 4.25 IUPHAR CHEMBL
Fatty acid-binding protein, liver Cytosolic other Kd 5.22 CHEMBL

External reference:

IDSource
4018482 VUID
N0000146804 NUI
D00279 KEGG_DRUG
2594 RXNORM
C0009002 UMLSCUI
CHEBI:3750 CHEBI
CHEMBL565 ChEMBL_ID
DB00636 DRUGBANK_ID
D002994 MESH_DESCRIPTOR_UI
2796 PUBCHEM_CID
2667 IUPHAR_LIGAND_ID
1530 INN_ID
HPN91K7FU3 UNII
348 MMSL
4474 MMSL
d00196 MMSL
002056 NDDF
387439004 SNOMEDCT_US
77035009 SNOMEDCT_US
C0009003 UMLSCUI
2797 PUBCHEM_CID
2439 INN_ID
4018482 VANDF
D002995 MESH_DESCRIPTOR_UI
CHEBI:34648 CHEBI
HPN91K7FU3 INXIGHT DRUGS

Pharmaceutical products:

None